Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan

Jan Show Chu, Chiun Sheng Huang, King Jen Chang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To evaluate the prognostic significance of proliferating cell nuclear antigen (PCNA) in breast cancer, an immunohistochemical assay was performed in 150 patients with invasive ductal carcinomas. The PCNA labeling index (PCNA-LI) was classified into two subgroups at a cut-off point of 45% that gave the best prognostic estimates for PCNA in survival analyses. Seventy-eight tumors had a low PCNA-LI of ≤45% and 72 tumors had a high PCNA-LI of >45%. A high PCNA-LI correlated significantly with p53 overexpression (P

Original languageEnglish
Pages (from-to)145-152
Number of pages8
JournalCancer Letters
Volume131
Issue number2
DOIs
Publication statusPublished - Sep 25 1998
Externally publishedYes

Fingerprint

Carcinoma, Ductal, Breast
Proliferating Cell Nuclear Antigen
Taiwan
Ductal Carcinoma
Survival Analysis
Neoplasms
Breast Neoplasms

Keywords

  • Breast cancer
  • Immunohistochemistry
  • p53
  • PCNA

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan. / Chu, Jan Show; Huang, Chiun Sheng; Chang, King Jen.

In: Cancer Letters, Vol. 131, No. 2, 25.09.1998, p. 145-152.

Research output: Contribution to journalArticle

@article{bc95af85eee74df8803efda030f3bf15,
title = "Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan",
abstract = "To evaluate the prognostic significance of proliferating cell nuclear antigen (PCNA) in breast cancer, an immunohistochemical assay was performed in 150 patients with invasive ductal carcinomas. The PCNA labeling index (PCNA-LI) was classified into two subgroups at a cut-off point of 45{\%} that gave the best prognostic estimates for PCNA in survival analyses. Seventy-eight tumors had a low PCNA-LI of ≤45{\%} and 72 tumors had a high PCNA-LI of >45{\%}. A high PCNA-LI correlated significantly with p53 overexpression (P",
keywords = "Breast cancer, Immunohistochemistry, p53, PCNA",
author = "Chu, {Jan Show} and Huang, {Chiun Sheng} and Chang, {King Jen}",
year = "1998",
month = "9",
day = "25",
doi = "10.1016/S0304-3835(98)00118-9",
language = "English",
volume = "131",
pages = "145--152",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan

AU - Chu, Jan Show

AU - Huang, Chiun Sheng

AU - Chang, King Jen

PY - 1998/9/25

Y1 - 1998/9/25

N2 - To evaluate the prognostic significance of proliferating cell nuclear antigen (PCNA) in breast cancer, an immunohistochemical assay was performed in 150 patients with invasive ductal carcinomas. The PCNA labeling index (PCNA-LI) was classified into two subgroups at a cut-off point of 45% that gave the best prognostic estimates for PCNA in survival analyses. Seventy-eight tumors had a low PCNA-LI of ≤45% and 72 tumors had a high PCNA-LI of >45%. A high PCNA-LI correlated significantly with p53 overexpression (P

AB - To evaluate the prognostic significance of proliferating cell nuclear antigen (PCNA) in breast cancer, an immunohistochemical assay was performed in 150 patients with invasive ductal carcinomas. The PCNA labeling index (PCNA-LI) was classified into two subgroups at a cut-off point of 45% that gave the best prognostic estimates for PCNA in survival analyses. Seventy-eight tumors had a low PCNA-LI of ≤45% and 72 tumors had a high PCNA-LI of >45%. A high PCNA-LI correlated significantly with p53 overexpression (P

KW - Breast cancer

KW - Immunohistochemistry

KW - p53

KW - PCNA

UR - http://www.scopus.com/inward/record.url?scp=0031786208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031786208&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(98)00118-9

DO - 10.1016/S0304-3835(98)00118-9

M3 - Article

C2 - 9851246

AN - SCOPUS:0031786208

VL - 131

SP - 145

EP - 152

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -